Patents by Inventor Ulf Reimer
Ulf Reimer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230406902Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.Type: ApplicationFiled: May 12, 2023Publication date: December 21, 2023Inventors: Ugur Sahin, Matin Daneschdar, Hans-Ulrich Schmoldt, Laura-Marie Kring (née Plum), Markus Fiedler, Ulf Reimer, Karsten Schnatbaum
-
Patent number: 11046745Abstract: The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3?). These molecules compete with CD3? for binding to a CD3? binding domain. e.g. a CD3? binding domain of an antibody, and are capable of detecting antibodies against CD3?. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3? antibody purification and the detection of anti-CD3? antibodies in biological samples.Type: GrantFiled: July 14, 2015Date of Patent: June 29, 2021Assignees: BioNTech SE, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, JPT Peptide Technologies GmbHInventors: Ugur Sahin, Laura Marie Kring, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt, Ulf Reimer, Karsten Schnatbaum
-
Patent number: 11001613Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.Type: GrantFiled: August 18, 2017Date of Patent: May 11, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
-
Patent number: 10858415Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.Type: GrantFiled: January 29, 2014Date of Patent: December 8, 2020Assignees: TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTTENBERG-UNIVERSITAT MAINZ GEMEINNUIZIGE GMBH, JPT PEPTIDE TECHNOLOGIES GMBH, BIONTECH SEInventors: Ugur Sahin, Matin Daneschdar, Hans-Ulrich Schmoldt, Laura-Marie Kring (née Plum), Markus Fiedler, Ulf Reimer, Karsten Schnatbaum
-
Publication number: 20200031898Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.Type: ApplicationFiled: October 7, 2019Publication date: January 30, 2020Inventors: Ugur Sahin, Matin Daneschdar, Hans-Ulrich Schmoldt, Laura-Marie Kring (née Plum), Markus Fiedler, Ulf Reimer, Karsten Schnatbaum
-
Publication number: 20190070248Abstract: The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3?). These molecules compete with CD3? for binding to a CD3? binding domain. e.g. a CD3? binding domain of an antibody, and are capable of detecting antibodies against CD3?. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3? antibody purification and the detection of anti-CD3? antibodies in biological samples.Type: ApplicationFiled: July 14, 2015Publication date: March 7, 2019Inventors: Ugur Sahin, Laura Marie Kring, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt, Ulf Reimer, Karsten Schnatbaum
-
Patent number: 10196423Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: May 9, 2018Date of Patent: February 5, 2019Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Helberg
-
Publication number: 20180334477Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: May 9, 2018Publication date: November 22, 2018Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Helberg
-
Patent number: 9982016Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: July 10, 2017Date of Patent: May 29, 2018Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20180072784Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.Type: ApplicationFiled: August 18, 2017Publication date: March 15, 2018Applicants: Baxalta GmbH, Baxalta IncorporatedInventors: Michael DOCKAL, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
-
Publication number: 20170313743Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: July 10, 2017Publication date: November 2, 2017Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 9777051Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.Type: GrantFiled: March 14, 2013Date of Patent: October 3, 2017Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
-
Patent number: 9745344Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: August 12, 2015Date of Patent: August 29, 2017Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20160347815Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.Type: ApplicationFiled: January 29, 2014Publication date: December 1, 2016Inventors: Ugur Sahin, Matin Daneschdar, Hans-Ulrich Schmoldt, Laura Marie Plum, Markus Fiedler, Ulf Reimer, Karsten Schnatbaum
-
Patent number: 9458198Abstract: Disclosed are cyclic, peptide-based novel compounds having NPR-B agonistic activity. Preferred compounds are cyclic peptides containing conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. In some embodiments, provided herein are a cyclic peptide compound with a ring size that is significantly reduced as compared to known NPR-B agonists, such as CNP.Type: GrantFiled: June 12, 2013Date of Patent: October 4, 2016Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20160194357Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: August 12, 2015Publication date: July 7, 2016Inventors: Frank Ostercamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20160153994Abstract: The present invention relates to an in vitro method for diagnosing Chronic Fatigue Syndrome by determining the presence, absence or the amount of at least one marker characteristic of an Epstein-Barr virus (EBV) infection in a sample obtained from the body of an individual. Specifically, the marker characteristic of EBV infection is selected from the group consisting of EBNA1, EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26. Furthermore, the invention relates to a device for the diagnosis of Chronic Fatigue Syndrome, wherein the device comprises a solid phase having immobilized thereon at least one marker or protein fragment thereof, wherein the marker is selected from the group consisting of EBNA1, EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26. In addition, the invention relates to the use of at least one marker or a protein fragment thereof for diagnosis of Chronic Fatigue, wherein the marker is selected from the group consisting of EBNA1 EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26.Type: ApplicationFiled: June 10, 2014Publication date: June 2, 2016Inventors: Carmen Scheibenbogen, Hans-Dieter Volk, Josef Priller, Klemens Ruprecht, Ulf Reimer, Holger Wenschuh
-
Patent number: 9169293Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: August 28, 2013Date of Patent: October 27, 2015Assignee: Shire Orphan Thereapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20130345394Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: Alcon Research, Ltd.Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 8546523Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: September 23, 2010Date of Patent: October 1, 2013Assignee: Alcon Research, Ltd.Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg